ClinicalTrials.gg
RecruitingNCT06977035Updated May 12, 2026

Nerve Conduction Study for Assessment of Peripheral Neuropathy in Rheumatoid Arthritis Patients on the Janus Kinase Inhibitor Baricitinib

An interventional study of Nerve Conduction Study in Rheumatoid Arthritis, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Sohag University · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Arthritis, Rheumatoid by Sohag University — 10 open to participants now, 11 under way, 1 of them phase 3. Arthritis, Rheumatoid · Sohag University.

Started
2025
with 2 others
No phase
7 of 20
2 open now
Primary completion
2025-11
later than 3 of 10 live
Registered
13th of 20
by date

Among the 20 studies in Arthritis, Rheumatoid by Sohag University, this one is one of 3 that started in 2025, is one of 7 with no phase, reaches primary completion later than 3 of the 10 other live ones, and was the 13th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

10 of the 20 studies in Arthritis, Rheumatoid by Sohag University are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Arthritis, Rheumatoid by Sohag University, or all of them as a file.
02

Study summary

Rheumatoid arthritis is a chronic, systemic, autoimmune inflammatory disease that mainly affects the joints and periarticular soft tissues. Baricitinib (Olumiant®) is an oral, targeted synthetic DMARD that inhibits JAK1 and JAK2, which are implicated in the pathogenesis of rheumatoid arthritis (RA). Nerve conduction studies (NCSs) are an essential tool in the evaluation of the peripheral nervous system. The sensory nerve action potential (SNAP) provides information on the sensory nerve axon and its pathway from the distal receptors in the skin to the dorsal root ganglia, while the compound muscle action potential (CMAP) is an assessment of the motor nerve fibers from their origins in the anterior horn cell to their termination along muscle fibers.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients fulfill the 2010 ACR/EULAR classification criteria of RA
  2. Age above 18 years old.
  3. Patient cooperative and can answer questions

Exclusion criteria

Exclusion Criteria:

  1. Other rheumatologic or collagen diseases.
  2. Age below 18 years and above 65 years.
  3. Uncooperative patients.
  4. Patients with other causes of peripheral neuropathy as Diabetes mellitus.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Rheumatoid Arthritis patients on Baricitinib treatment

    Device: Nerve Conduction Study

  • Active comparator
    Rheumatoid Arthritis patient on conventional synthetic DMARD

    Device: Nerve Conduction Study

Interventions

  • DeviceNerve Conduction Study

    Sensory and Motor Nerve Conduction study on upper and lower limbs.

06

What researchers measure

Primary outcomes

  1. prevalence of Peripheral Neuropathy in Rheumatoid Arthritis Patients on Baricitinib

    Assessment of Peripheral Neuropathy in Rheumatoid Arthritis Patients on Baricitinib in comparison to those on conventional synthetic DMARDs.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Di Matteo A, Bathon JM, Emery P. Rheumatoid arthritis. Lancet. 2023 Nov 25;402(10416):2019-2033. doi: 10.1016/S0140-6736(23)01525-8. Epub 2023 Oct 27. PubMed 38240831 ↗
  • Grassi W, De Angelis R, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis. Eur J Radiol. 1998 May;27 Suppl 1:S18-24. doi: 10.1016/s0720-048x(98)00038-2. PubMed 9652497 ↗
  • Al-Salama ZT, Scott LJ. Baricitinib: A Review in Rheumatoid Arthritis. Drugs. 2018 May;78(7):761-772. doi: 10.1007/s40265-018-0908-4. PubMed 29687421 ↗
  • Mallik A, Weir AI. Nerve conduction studies: essentials and pitfalls in practice. J Neurol Neurosurg Psychiatry. 2005 Jun;76 Suppl 2(Suppl 2):ii23-31. doi: 10.1136/jnnp.2005.069138. No abstract available. PubMed 15961865 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Nov 2025, 6 months.

Of 293 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's 6 months is below that.

Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2025
First posted
May 16, 2025
StartActual
May 5, 2025
Primary completionActual
Nov 5, 2025
CompletionEst.
Jun 2026
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06977035
Lead sponsor
Sohag University
Responsible party
Sara Khairy Mohamed (Resident at Physical medicine, Rheumatology and Rehabilitation Department, Sohag University Hospital, Sohag University) — Principal investigator
First posted
May 16, 2025
Start date
May 5, 2025
Primary completion
Nov 5, 2025
Completion
Jun 2026 (estimated)
Last update
May 12, 2026

Study contacts

Sara K Mohamed, Resident
Contact
sara.khairy@med.sohag.edu.eg
01155791113
Ahmed R Alagamy, Associate Professor
Contact
ahmed_radwan@med.sohag.edu.eg
01092914019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion